Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia.
Error 404 - Not Found
It seems that you were looking for something. We re-designed our web site and re-worked its structure, so directories have been changed. Maybe you wanted to find out about us
, contact us
or catch up on the latest news